Summary
Government regulators in Britain are asking Novartis and Bristol-Myers Squibb to help pay for their leukemia drugs. In a statement, the National Institute for Health and Clinical Excellence (NICE) took issue with price points on BMS's Sprycel and Tasigna -- telling Bloomberg that the drugs cost around $50,000 each for a year supply -- and said there wasn't sufficient evidence for recommending the drug to patients. In the US, Novartis has launched several Web sites to help patients cope with chronic myelogenous leukemia, and pay for treatment.
See the full content of this document
Extract
Pharma Should Help Pay for Cancer Rx
GOVERNMENT regulators in Britain are asking Novartis and Bristol-Myers Squibb to help pay for ...
See the full content of this document
Sponsored links
